Company
Evolus, Inc.
Headquarters: Newport Beach, CA, United States
Employees: 167
CEO: Mr. David Moatazedi
Market Cap
$597.7 Million
USD as of July 1, 2025
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $202.1 M |
| EBITDA | $-30,974,000 |
| Gross Profit TTM | $140.5 M |
| Profit Margin | -30.52% |
| Operating Margin | -8.33% |
| Quarterly Revenue Growth | 39.80% |
Stocks & Indices
Evolus, Inc. has the following listings and related stock indices.
Stock: NASDAQ: EOLS wb_incandescent
Stock: FSX: EVL wb_incandescent